G protein coupled receptor 41 regulates fibroblast activation in pulmonary fibrosis via Gαi/o and downstream Smad2/3 and ERK1/2 phosphorylation
Pharmacological Research · 2023
DOI: 10.1016/j.phrs.2023.106754 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacological Research, 2023. Verfasst von Zhengnan Ren und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine and School of Food Science and Technology, Jiangnan University, Wuxi, China; State Key Laboratory of Food Science and Technology, …. Hauptthemen laut MEDLINE: Pulmonary Fibrosis. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation, Natural Science Foundation of Jiangsu Province.
Abstract (Originalsprache)
Pulmonary fibrosis is a progressive and fatal fibrotic lung disease with mysterious pathogenesis and limited effective therapies. G protein-coupled receptors (GPRs) participate in a variety of physiologic functions, and several GPRs have critical fibrosis-promoting or -inhibiting roles in pulmonary fibrosis. Here, we explored the role of GPR41 in the pathobiology of pulmonary fibrosis. We found that GPR41 expression was elevated in lung tissues of mice with bleomycin-induced pulmonary fibrosis and lung fibroblasts treated with transforming growth factor-β1 (TGF-β1). Knockout of GPR41 attenuated pulmonary fibrosis in mice, as evidenced by improved lung morphology, decreased lung weight and collagen secretion, and down-regulated α-SMA, collagen type I alpha and fibronectin expression in lungs. Additionally, GPR41 knockout inhibited the differentiation of fibroblasts to myofibroblasts, and decreased myofibroblast migration. By further mechanistic analysis, we demonstrated that GPR41 regulated TGF-β1-induced fibroblast-to-myofibroblast differentiation and Smad2/3 and ERK1/2 phosphorylation via its Gαi/o subunit but not Gβγ subunit. Together, our data indicate that GPR41 is involved in pulmonary fibroblast activation and fibrosis, and GPR41 represents a potential therapeutic target for pulmonary fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine and School of Food Science and Technology, Jiangnan University, Wuxi, China; State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, China.
- School of Medicine and School of Food Science and Technology, Jiangnan University, Wuxi, China.
- School of Medicine and School of Food Science and Technology, Jiangnan University, Wuxi, China. Electronic address: llpan@jiangnan.edu.cn.
- School of Medicine and School of Food Science and Technology, Jiangnan University, Wuxi, China; State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, China. Electronic address: jiasun@jiangnan.…
Förderung
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Natural Science Foundation of Jiangsu Province
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Ren, Z., Pan, X., Li, J., Dong, X., Tu, X., Pan, L. L., & Sun, J. (2023). G protein coupled receptor 41 regulates fibroblast activation in pulmonary fibrosis via Gαi/o and downstream Smad2/3 and ERK1/2 phosphorylation. Pharmacological Research. https://doi.org/10.1016/j.phrs.2023.106754
Vancouver
Ren Z, Pan X, Li J, Dong X, Tu X, Pan LL, et al. G protein coupled receptor 41 regulates fibroblast activation in pulmonary fibrosis via Gαi/o and downstream Smad2/3 and ERK1/2 phosphorylation. Pharmacological Research. 2023. doi:10.1016/j.phrs.2023.106754
BibTeX
@article{Ren2023,
author = {Ren, Zhengnan and Pan, Xiaohua and Li, Jiahong and Dong, Xiaoliang and Tu, Xing and Pan, Li-Long and Sun, Jia},
title = {G protein coupled receptor 41 regulates fibroblast activation in pulmonary fibrosis via Gαi/o and downstream Smad2/3 and ERK1/2 phosphorylation},
journal = {Pharmacological Research},
year = {2023},
doi = {10.1016/j.phrs.2023.106754}
}
EUVIMED